Chardan Capital Decreases Earnings Estimates for uniQure

uniQure N.V. (NASDAQ:QURE) – Chardan Capital decreased their FY2026 earnings per share estimates for uniQure in a report released on Tuesday, November 4th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnology company will post earnings per share of ($3.39) for the year, down from their prior estimate of ($3.20). Chardan Capital currently has a “Buy” rating and a $53.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

Several other research firms have also recently issued reports on QURE. HC Wainwright dropped their price target on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday. Cantor Fitzgerald upped their price objective on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Stifel Nicolaus raised their price objective on shares of uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Wells Fargo & Company increased their target price on uniQure from $65.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Finally, William Blair lowered uniQure from an “outperform” rating to a “market perform” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $66.75.

uniQure Stock Down 3.4%

NASDAQ:QURE traded down $0.94 during trading hours on Friday, hitting $26.57. The stock had a trading volume of 1,739,245 shares, compared to its average volume of 2,197,432. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The business has a 50 day simple moving average of $41.84 and a two-hundred day simple moving average of $24.06. The company has a market cap of $1.46 billion, a PE ratio of -6.80 and a beta of 0.59. uniQure has a 1-year low of $5.50 and a 1-year high of $71.50.

Insider Buying and Selling at uniQure

In other news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 38,810 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the sale, the director owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 283,126 shares of company stock worth $11,505,677 over the last ninety days. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Aberdeen Group plc lifted its holdings in uniQure by 24.2% during the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after buying an additional 535,163 shares in the last quarter. Jennison Associates LLC acquired a new position in uniQure during the second quarter worth $1,952,000. Y Intercept Hong Kong Ltd acquired a new stake in uniQure during the 2nd quarter worth approximately $872,000. Cubist Systematic Strategies LLC acquired a new position in uniQure in the 1st quarter valued at $2,562,000. Finally, OMERS ADMINISTRATION Corp bought a new position in uniQure during the 1st quarter worth $152,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.